Featured News
(STAT Plus) June 1, 2020 - The annual meeting American Society of Clinical Oncology (ASCO) concluded on Sunday.
The closely-followed cancer research meeting is typically held over five days in Chicago. But for the first time, this...
(BioSpace) Jun 1, 2020 - The American Society of Clinical Oncology (ASCO) 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a...
(Yale) May 28, 2020 - According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage,...
(ECOG-ACRIN) May 28, 2020 - Phase 3 trial E2108—conducted to resolve conflicting data from earlier randomized studies—found that surgery and radiation after initial systemic therapy do not improve overall survival for women who first...
(ECOG-ACRIN) May 28, 2020 - Planned interim analysis of efficacy and toxicity in the randomized phase 3 ENDURANCE (E1A11) trial selected by ASCO 2020 for a late-breaking plenary presentation.
The combination of carfilzomib,...
(AstraZeneca) May 29, 2020 - 61.9% of patients with HER2-mutant metastatic non-small cell lung cancer treated with Enhertu achieved a tumour response.
(AstraZeneca) May 29, 2020 - Results from the Phase II DESTINY-CRC01 trial of AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) demonstrated clinically meaningful activity in patients...
(AstraZeneca) May 29, 2020 - First HER2-directed medicine to show an improvement in overall survival for previously treated metastatic gastric cancer with a 41% reduction in the risk of death vs. chemotherapy.
(The Center for Biosimilars) May 31, 2020 - Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, say investigators in a presentation at...
(The Center for Biosimilars) May 31, 2020 - When used as a primary prophylaxis, biosimilar filgrastim (Zarxio), was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according...
More News
(ACCCBuzz Blog) June 12, 2020 - At the recent American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, ACCC presented seven abstracts that capture data spanning the organization’s diverse provider education...
(Johns Hopkins) June 10, 2020 - Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American...
(MedPage Today) June 8, 2020 - Consensus on testing for dMMR/MSI-H, but strategies vary for other biomarkers.
(Medscape Medical News) June 8, 2020 - Continuing adjuvant imatinib (Gleevec, Novartis) for 3 years rather stopping at 1 year in patients with high-risk gastrointestinal stromal tumor (GIST) could halve the death rate over 10 years,...
(BioPharma Dive) June 5, 2020 - The China-based cell therapy developer, whose myeloma therapy is a rival to one from Bristol Myers and Bluebird, outraised this year's previous top initial biotech stock offering.
(Medscape Medical News) June 4, 2020 - The world's largest oncology meeting went online to mixed reviews. Doubts and hopes coexist about an in-person meeting next year.
(MedPage Today) June 3, 2020 - Response rates of 70-100% with BCMA-targeted products for heavily treated disease.
(MedPage Today) June 3, 2020 - Overall response rate of 36% with tumor-infiltrating lymphocytes in heavily treated patients.
(UPI/HealthDay News) June 3, 2020 - Screening for breast and ovarian cancer genes might be added to the list of medical tests that can be safely and effectively done from home, new research suggests.
(WebMD/Medscape Medical News) June 2, 2020 - The proton pump inhibitor (PPI) omeprazole used with chemotherapy may help shrink tumors in patients with triple-negative breast cancer.
Follow @OBRTweets